{"trials":[{"id":3440,"nct_id":"NCT07296094","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial","sponsor":"Brigham and Women's Hospital","registry_url":"https://clinicaltrials.gov/study/NCT07296094","tracker_url":"publication.php?id=3440","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-24","start_date":"2026-11-15","primary_completion_date":"2029-12-01","completion_date":"2030-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":36,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ea17498fc8f1ee10ccde7d5207d959cb8f2fd7095ee234897659fb05d1422118","facility":"Brigham and Women's Hospital","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977}],"countries":["United States"]},{"id":3587,"nct_id":"NCT06349083","title":"Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06349083","tracker_url":"publication.php?id=3587","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-09-02","start_date":"2026-09-01","primary_completion_date":"2030-05","completion_date":"2030-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Inactive Placebo","type":"OTHER"},{"name":"Supportive therapy sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3662,"nct_id":"NCT07638553","title":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sponsor":"Centre Hospitalier Universitaire de Nīmes","registry_url":"https://clinicaltrials.gov/study/NCT07638553","tracker_url":"publication.php?id=3662","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-07-01","start_date":"2026-06-30","primary_completion_date":"2030-06","completion_date":"2030-06","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":172,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Alcohol Use Disorder","Depressive Sympotoms","Psilocybin"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"Psilocybin (low dose)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"323f6a0d326702feb35e14a7b9184860791df3488ef3495f35a0de3236897eb0","facility":"Centre Hospitalier de la Côte Basque","city":"Bayonne","region":"","country":"France","lat":43.493160000000003,"lon":-1.4730000000000001},{"key":"5ffc1075f6bec0dadbe8bc3e065b0e1b877e363dbf6627b545bf4beffff70757","facility":"CHU Besançon","city":"Besançon","region":"","country":"France","lat":47.248779999999996,"lon":6.0181500000000003},{"key":"a6fd2e2e6ed56330ba623e90ee634f2d4915008c80b207dde3ed9faf47960e8d","facility":"CHU de Bordeaux","city":"Bordeaux","region":"","country":"France","lat":44.841239999999999,"lon":-0.58045999999999998},{"key":"14ea4a2b72ea454ee54e0e0774dcd9904223f73df3e3c531e7d5f0cfa141d839","facility":"CHU Brest","city":"Brest","region":"","country":"France","lat":48.39029,"lon":-4.4862799999999998},{"key":"f89e51a603fb7d3311c5aa5e1f5fa8b931a29eab96f579366c7020edef6d63eb","facility":"CH Le Vinatier","city":"Bron","region":"","country":"France","lat":45.73865,"lon":4.91303},{"key":"979bc0acd73468b3e9e5e478d1eb8b6146cdb655e43714015ace7d5e264ec03f","facility":"CHU de Nantes","city":"Nantes","region":"","country":"France","lat":47.21725,"lon":-1.5533600000000001},{"key":"4a89439659e3f06e4c831d2ab54c7949dfe24a09c19f411896d75ff90f0f0fde","facility":"CHU de Nîmes","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"3f02e2b16edbfc081f5b9dfd08b8a203c4b47bf73ba2fa3f66915ff73cb56a9b","facility":"CHU Saint-Etienne","city":"Saint-Priest","region":"","country":"France","lat":45.696510000000004,"lon":4.9438500000000003}],"countries":["France"]},{"id":3456,"nct_id":"NCT05416229","title":"The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.","sponsor":"Anders Fink-Jensen, MD, DMSci","registry_url":"https://clinicaltrials.gov/study/NCT05416229","tracker_url":"publication.php?id=3456","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-03","last_update_date":"2026-03-24","start_date":"2023-09-01","primary_completion_date":"2025-12-22","completion_date":"2025-12-22","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Maltodextrin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"89e2d67761ad37e19e964873766cfa07d5443f9dabbd7226a4f9fcb320860b0c","facility":"Psychiatric Center Copenhagen, Frederiksberg Hospital","city":"Frederiksberg","region":"","country":"Denmark","lat":55.679380000000002,"lon":12.53463}],"countries":["Denmark"]},{"id":3493,"nct_id":"NCT04620759","title":"Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04620759","tracker_url":"publication.php?id=3493","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-13","start_date":"2021-04-14","primary_completion_date":"2026-03-02","completion_date":"2027-03-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder","Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3444,"nct_id":"NCT06405607","title":"Psilocybin vs Ketamine for Alcohol Use Disorder","sponsor":"University of Iowa","registry_url":"https://clinicaltrials.gov/study/NCT06405607","tracker_url":"publication.php?id=3444","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-28","start_date":"2025-06-12","primary_completion_date":"2028-04","completion_date":"2028-04","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":80,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder","Alcohol Dependence","Alcohol Abuse"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"96f2bd88eed1d3818ed1f1051b3996f8f528fdb49be756ea1e8244ba9e93f7ba","facility":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998}],"countries":["United States"]},{"id":3443,"nct_id":"NCT05421065","title":"Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder","sponsor":"Peggy C Nopoulos","registry_url":"https://clinicaltrials.gov/study/NCT05421065","tracker_url":"publication.php?id=3443","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-17","start_date":"2024-02-02","primary_completion_date":"2025-08-30","completion_date":"2026-09","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"097d4730cb01f99d9d2fa793ee390c7860c40b2cbc6537289fd39fa1de4c2ebc","facility":"University of Iowa","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998}],"countries":["United States"]},{"id":3588,"nct_id":"NCT07189988","title":"Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism","sponsor":"Healing Advocacy Fund","registry_url":"https://clinicaltrials.gov/study/NCT07189988","tracker_url":"publication.php?id=3588","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-09","last_update_date":"2025-09-24","start_date":"2025-03-05","primary_completion_date":"2026-06-10","completion_date":"2026-08-05","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"psilocybin","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"2e5a211e4aae826703cd0d478a5304735037ed9f6e5d1fffb9064c5fa43504bb","facility":"Innertrek Patient Service Center","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621}],"countries":["United States"]},{"id":3428,"nct_id":"NCT05646303","title":"A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sponsor":"Clairvoyant Therapeutics","registry_url":"https://clinicaltrials.gov/study/NCT05646303","tracker_url":"publication.php?id=3428","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-09","last_update_date":"2024-08-15","start_date":"2022-05-02","primary_completion_date":"2024-08-31","completion_date":"2024-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":128,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7921922108da606383f02d461f4df4e14db71c279c22c13f6e0098569e6fc045","facility":"Sabi Mind","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"b6145ff487ffb39fe26ce240998c399fbf6f9a455da2b4bd7a6baefc497639eb","facility":"Okanagan Clinical Trials","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568},{"key":"f382a179650c2df27e8a44e5fbd93e67557feb21753716040410f9b7f60eb029","facility":"Centre for Neurology Studies","city":"Surrey","region":"British Columbia","country":"Canada","lat":49.106349999999999,"lon":-122.82509},{"key":"67a68181704a60b202e5bd17a9943b90ad9f4f4bae50a883bcee9366ae6b07ab","facility":"University of British Columbia, Department of Psychiatry, BRAIN Lab","city":"Vancouver","region":"British Columbia","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"48228a6e53745d2e5d9ebb9d9e380833b371fa7e760c88385827be732372c4f7","facility":"Centricity Research","city":"Halifax","region":"Nova Scotia","country":"Canada","lat":44.642690000000002,"lon":-63.576880000000003},{"key":"51a9a92a0508b764f9a4517d8d60933b3ee3ba0964375b23c07f442f64b82278","facility":"MacAnxiety Research Centre","city":"Hamilton","region":"Ontario","country":"Canada","lat":43.250109999999999,"lon":-79.849630000000005},{"key":"e6f14c804d63d788a9de79fa6c9092129f515985d376c7b8cc0020b9e61c1729","facility":"Department of Psychiatry, Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"d06e48f11f12f9cf06e95d71a691ebf90c8fe98aefa9008cd221096d6eabb8b9","facility":"Research Center Oxidi Oy / Addiktum Oy","city":"Helsinki","region":"","country":"Finland","lat":60.169519999999999,"lon":24.935449999999999},{"key":"a967236f529970e305e31c0bb38c4df0951a3d9fa9defea114930d40bbcb3df8","facility":"A-Klinikka","city":"Kouvola","region":"","country":"Finland","lat":60.866669999999999,"lon":26.699999999999999},{"key":"097f01f888974a19c581a1a4a48207f44890c9eb5fc62fd738265f1e44166755","facility":"Mentacare Oy","city":"Oulu","region":"","country":"Finland","lat":65.012360000000001,"lon":25.468160000000001},{"key":"2b75d8f2d0990670d7c5884774f83a08cea77ea8701cbb5acf36b7aa6d726817","facility":"Addiktum Oy","city":"Turku","region":"","country":"Finland","lat":60.451479999999997,"lon":22.268689999999999}],"countries":["Canada","Finland"]},{"id":3445,"nct_id":"NCT06444243","title":"A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder","sponsor":"University of Sydney","registry_url":"https://clinicaltrials.gov/study/NCT06444243","tracker_url":"publication.php?id=3445","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2024-06","last_update_date":"2024-06-10","start_date":"2024-09","primary_completion_date":"2025-07","completion_date":"2025-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder","Alcohol Dependence","Depression","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3632,"nct_id":"NCT05995769","title":"Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT05995769","tracker_url":"publication.php?id=3632","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2023-08","last_update_date":"2024-05-07","start_date":"2024-03-20","primary_completion_date":"2027-10-01","completion_date":"2027-10-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":128,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder","Alcoholism"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529}],"countries":["Canada"]},{"id":3573,"nct_id":"NCT04141501","title":"Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder","sponsor":"University of Zurich","registry_url":"https://clinicaltrials.gov/study/NCT04141501","tracker_url":"publication.php?id=3573","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-09","last_update_date":"2023-09-21","start_date":"2020-06-08","primary_completion_date":"2023-03-14","completion_date":"2023-09-14","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":37,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo oral capsule","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3568,"nct_id":"NCT04410913","title":"Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder","sponsor":"Keith Heinzerling","registry_url":"https://clinicaltrials.gov/study/NCT04410913","tracker_url":"publication.php?id=3568","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2023-01","last_update_date":"2023-01-17","start_date":"2021-02-18","primary_completion_date":"2023-02","completion_date":"2023-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin plus Visual Healing Set and Setting","type":"DRUG"},{"name":"Psilocybin plus Standard Set and Setting","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"16d9ba9702f70f239da1a221cfefc364c6d5b87b4d0db3a5b080e4cd80046ae8","facility":"Pacific Treatment & Research in Psychedelics","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001}],"countries":["United States"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2020":1,"2021":2,"2022":1,"2023":1,"2024":3,"2025":2,"2026":3},"statuses":{"Recruiting":4,"Active, not recruiting":4,"Completed":2,"Unknown status":2,"Not yet recruiting":1},"conditions":{"Alcohol Use Disorder":13,"Alcohol Dependence":2,"Depressive Sympotoms":1,"Psilocybin":1,"Major Depressive Disorder":1,"Alcohol Abuse":1,"Depression":1,"Anxiety":1,"Alcoholism":1},"sites":[{"key":"ea17498fc8f1ee10ccde7d5207d959cb8f2fd7095ee234897659fb05d1422118","facility":"Brigham and Women's Hospital","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"323f6a0d326702feb35e14a7b9184860791df3488ef3495f35a0de3236897eb0","facility":"Centre Hospitalier de la Côte Basque","city":"Bayonne","region":"","country":"France","lat":43.493160000000003,"lon":-1.4730000000000001},{"key":"5ffc1075f6bec0dadbe8bc3e065b0e1b877e363dbf6627b545bf4beffff70757","facility":"CHU Besançon","city":"Besançon","region":"","country":"France","lat":47.248779999999996,"lon":6.0181500000000003},{"key":"a6fd2e2e6ed56330ba623e90ee634f2d4915008c80b207dde3ed9faf47960e8d","facility":"CHU de Bordeaux","city":"Bordeaux","region":"","country":"France","lat":44.841239999999999,"lon":-0.58045999999999998},{"key":"14ea4a2b72ea454ee54e0e0774dcd9904223f73df3e3c531e7d5f0cfa141d839","facility":"CHU Brest","city":"Brest","region":"","country":"France","lat":48.39029,"lon":-4.4862799999999998},{"key":"f89e51a603fb7d3311c5aa5e1f5fa8b931a29eab96f579366c7020edef6d63eb","facility":"CH Le Vinatier","city":"Bron","region":"","country":"France","lat":45.73865,"lon":4.91303},{"key":"979bc0acd73468b3e9e5e478d1eb8b6146cdb655e43714015ace7d5e264ec03f","facility":"CHU de Nantes","city":"Nantes","region":"","country":"France","lat":47.21725,"lon":-1.5533600000000001},{"key":"4a89439659e3f06e4c831d2ab54c7949dfe24a09c19f411896d75ff90f0f0fde","facility":"CHU de Nîmes","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"3f02e2b16edbfc081f5b9dfd08b8a203c4b47bf73ba2fa3f66915ff73cb56a9b","facility":"CHU Saint-Etienne","city":"Saint-Priest","region":"","country":"France","lat":45.696510000000004,"lon":4.9438500000000003},{"key":"89e2d67761ad37e19e964873766cfa07d5443f9dabbd7226a4f9fcb320860b0c","facility":"Psychiatric Center Copenhagen, Frederiksberg Hospital","city":"Frederiksberg","region":"","country":"Denmark","lat":55.679380000000002,"lon":12.53463},{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"96f2bd88eed1d3818ed1f1051b3996f8f528fdb49be756ea1e8244ba9e93f7ba","facility":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998},{"key":"097d4730cb01f99d9d2fa793ee390c7860c40b2cbc6537289fd39fa1de4c2ebc","facility":"University of Iowa","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998},{"key":"2e5a211e4aae826703cd0d478a5304735037ed9f6e5d1fffb9064c5fa43504bb","facility":"Innertrek Patient Service Center","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"7921922108da606383f02d461f4df4e14db71c279c22c13f6e0098569e6fc045","facility":"Sabi Mind","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"b6145ff487ffb39fe26ce240998c399fbf6f9a455da2b4bd7a6baefc497639eb","facility":"Okanagan Clinical Trials","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568},{"key":"f382a179650c2df27e8a44e5fbd93e67557feb21753716040410f9b7f60eb029","facility":"Centre for Neurology Studies","city":"Surrey","region":"British Columbia","country":"Canada","lat":49.106349999999999,"lon":-122.82509},{"key":"67a68181704a60b202e5bd17a9943b90ad9f4f4bae50a883bcee9366ae6b07ab","facility":"University of British Columbia, Department of Psychiatry, BRAIN Lab","city":"Vancouver","region":"British Columbia","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"48228a6e53745d2e5d9ebb9d9e380833b371fa7e760c88385827be732372c4f7","facility":"Centricity Research","city":"Halifax","region":"Nova Scotia","country":"Canada","lat":44.642690000000002,"lon":-63.576880000000003},{"key":"51a9a92a0508b764f9a4517d8d60933b3ee3ba0964375b23c07f442f64b82278","facility":"MacAnxiety Research Centre","city":"Hamilton","region":"Ontario","country":"Canada","lat":43.250109999999999,"lon":-79.849630000000005},{"key":"e6f14c804d63d788a9de79fa6c9092129f515985d376c7b8cc0020b9e61c1729","facility":"Department of Psychiatry, Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"d06e48f11f12f9cf06e95d71a691ebf90c8fe98aefa9008cd221096d6eabb8b9","facility":"Research Center Oxidi Oy / Addiktum Oy","city":"Helsinki","region":"","country":"Finland","lat":60.169519999999999,"lon":24.935449999999999},{"key":"a967236f529970e305e31c0bb38c4df0951a3d9fa9defea114930d40bbcb3df8","facility":"A-Klinikka","city":"Kouvola","region":"","country":"Finland","lat":60.866669999999999,"lon":26.699999999999999},{"key":"097f01f888974a19c581a1a4a48207f44890c9eb5fc62fd738265f1e44166755","facility":"Mentacare Oy","city":"Oulu","region":"","country":"Finland","lat":65.012360000000001,"lon":25.468160000000001},{"key":"2b75d8f2d0990670d7c5884774f83a08cea77ea8701cbb5acf36b7aa6d726817","facility":"Addiktum Oy","city":"Turku","region":"","country":"Finland","lat":60.451479999999997,"lon":22.268689999999999},{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007},{"key":"16d9ba9702f70f239da1a221cfefc364c6d5b87b4d0db3a5b080e4cd80046ae8","facility":"Pacific Treatment & Research in Psychedelics","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001}],"enrollment":{"sum":1081,"known_trials":13},"registry_checked_at_utc":"2026-10-09 01:24:43"}